Amgen Dismisses Roche’s Licensing Proposal For Mircera, Wants Injunction
Executive Summary
Amgen's latest court filing ridicules Roche's proposal for economic terms upon which a court would allow marketing of its pegylated epoetin Mircera
You may also be interested in...
Court May Ask Roche To Pay Amgen 22.5 Percent Royalty To Market Mircera
A district court judge issued a preliminary injunction blocking Roche's launch of Mircera (epoetin beta) in the United States and suggested the terms under which Roche might begin selling its anti-anemia drug
Court May Ask Roche To Pay Amgen 22.5 Percent Royalty To Market Mircera
A district court judge issued a preliminary injunction blocking Roche's launch of Mircera (epoetin beta) in the United States and suggested the terms under which Roche might begin selling its anti-anemia drug
Roche Plans At-Risk Launch Of Mircera, But Offers Amgen A 20% Royalty
Roche plans to move forward with an at-risk launch of Mircera (epoetin beta) if it does not receive a judicial ruling on its proposal to sell the anti-anemia drug at a reduced cost and pay Amgen a 20 percent royalty on sales. The company wants a court decision by the end of February